No Data
China Aprpoves Lukang Pharma Unit's Supplementary Drug Application for Heart Injection
Investors are paying attention to the progress of FT606. Shandong Lukang Pharmaceutical did not directly respond to the production time | Live coverage of the earnings conference
① The company's new synthetic biotechnology material product FT606 has attracted much attention. ② The pharmaceutical industry was in the traditional off-season in the third quarter, leading to a decline in the company's Q3 performance. ③ In the earnings conference, a questioner claiming to be an investor expressed dissatisfaction with the lack of interaction.
Shandong Lukang Pharmaceutical (600789.SH): Flupentixol Injection passed the generic drug consistency evaluation
Gelonghui November 5th | Shandong Lukang Pharmaceutical (600789.SH) announced that its holding subsidiary, Shandong Lukang Pharmaceutical Group Saite Co., Ltd., has received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration regarding the consistency evaluation of generic drug quality and efficacy for Flupentixol Injection. Flupentixol belongs to the butyrophenone class of antipsychotic drugs, its antipsychotic effect is achieved by blocking dopamine receptors in the brain and promoting the conversion of dopamine, exhibiting good anti-hallucination and anti-excitement effects. It has a strong blocking effect on extrapyramidal dopamine, as well as strong antiemetic effects.
Lukang Pharmaceutical Report for the Third Quarter of 2024
Shandong Lukang Pharmaceutical (600789.SH) released its performance for the first three quarters, with a net income of 0.347 billion yuan, an 80.24% year-on-year increase.
shandong lukang pharmaceutical (600789.SH) released the third quarter report of 2024, with the company's revenue for the first three quarters at 46...
Shandong Lukang PharmaceuticalLtd (SHSE:600789) Jumps 6.4% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
Is The Market Rewarding Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?No Data
No Data
